Key Drivers
- Strong Liquidity
- Heavy Losses
- Negative Cash Flow
AIAI Summary
ALMS should now be viewed less as a financing-risk biotech and more as a catalyst-driven clinical trade, because its $571M cash cushion buys time for envudeucitinib's psoriasis, SLE, and NDA milestones to re-rate the stock—but with valuation already elevated, the next data must prove durable differentiation and approvability or the current rally could fade quickly.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Heavy Losses
- •Negative Cash Flow
ALMS has strong liquidity and minimal debt, but persistent heavy losses, negative free cash flow, and poor expense control make its financial profile highly risky despite that balance-sheet strength.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance test
- •Cooling momentum
ALMS remains technically bullish with a 32% uptrend and higher lows, but the recent pullback from $28.14 suggests momentum is cooling and near-term consolidation toward $25 is possible.
Sharp 32% run-up followed by a pullback from the recent peak
Sentiment & News
Key News Insights:
- •Phase 3 strength
- •2026 catalysts
- •Dosing drawback
Alumis retained a renewed Buy rating on envudeucitinib, with strong Phase 3 data and multiple 2026 catalysts in psoriasis and SLE outweighing only a modest twice-daily dosing drawback.
The update is modestly positive for ALMS, as upcoming clinical and regulatory milestones could drive meaningful valuation upside if results hold up
Similar Companies in Healthcare
Other companies in the same sector with AI ratings